<DOC>
	<DOCNO>NCT00328874</DOCNO>
	<brief_summary>Study hypothesis : A 6-week p.o treatment 5 mg/Kg Coenzyme Q10 safe tolerable , increase brain 's metabolism ameliorate clinical symptom patient PSP .</brief_summary>
	<brief_title>Study About Safety Efficacy Coenzyme Q10 Progressive Supranuclear Palsy</brief_title>
	<detailed_description>Background Rationale : 1 . Progressive Supranuclear Palsy ( PSP , Steele-Richardson-Olszewski Syndrome ) sporadic neurodegenerative disorder result clinically Parkinson syndrome ( i.e . akinetic-rigid movement disorder ) prominent postural instability , oculomotor deficit , cognitive decline ( review : Albers Augood , 2001 ; Burn Lees , 2002 ) . With average annual incidence 5.3 per 100000 age-adjusted prevalence 6.4 per 100000 , PSP common motor-neuron disease ( Burn Lees , 2002 ) . There symptomatic treatment , PSP patient respond know therapy ( Albers Augood , 2001 ; Burn Lees , 2002 ) . The progression PSP rapid median survival onset symptom 5-10 year ( Albers Augood , 2001 ) . Presently , know effective symptomatic neuroprotective therapy PSP . 2 . Evidence suggest impairment mitochondrial energy metabolism PSP ( Albers Beal , 2002 ) : 1 . Reduced cerebral glucose ATP metabolism show functional imaging study PSP patient ( Forster et al. , 1988 ; Martinelli et al. , 2000 ) . 2 . Cybrid cell harbor mitochondrial gene PSP patient decrease ATP-levels complex I activity ( Swerdlow et al. , 2000 ; Albers et al. , 2001 ; Chirichigno et al. , 2002 ) . 3 . A tropical PSP-like tauopathy link clinically experimentally consumption fruit teas leave tropical plant annona muricata rich lipophilic complex I inhibitor ( Caparros-Lefebvre et al. , 1999 ; 2001 ) . These clinical observation suggest role mitochondrial dysfunction etiology PSP . 3.Coenzyme Q10 ( CoQ10 ) physiological electron recipient complex I. Exogenous CoQ10 ( 1 . ) enhance electron transport complex I ( 2 . ) powerfully scavenge free radical . Thus , CoQ10 show reduce toxicity complex I inhibitors vitro ( Menke et al. , 2003 ) vivo ( Beal et al. , 1998</detailed_description>
	<mesh_term>Paralysis</mesh_term>
	<mesh_term>Supranuclear Palsy , Progressive</mesh_term>
	<mesh_term>Coenzyme Q10</mesh_term>
	<mesh_term>Ubiquinone</mesh_term>
	<criteria>Diagnosis clinically probable PSP ( Litvan et al. , 1996 ) . Early stage PSP [ PSP stag system ≤ III ( Golbe , 1997 ) ] . Capability willingness give write informed consent participate study . Age &gt; 85 year . Parkinson syndromes PSP ( e.g . idiopathic Parkinson 's disease , multiple system atrophy , diffuse Lewy body disease , FTDP17 , symptomatic parkinsonism ) Dementia [ Mini Mental State Examination ( MMSE ) ≤ 24 ] History epilepsy , structural brain disease , brain surgery , electroconvulsive therapy History stroke relate onset progression PSP symptoms Arterial hypertension ( systolic &gt; 180 diastolic &gt; 110mm Hg ) Thyroid dysfunction require thyroxin supplementation ( CoQ10 may change metabolism ) Presence serious illness Insufficient contraception male premenopausal female participant . Accepted mean contraception hormonal contraception , intrauterine device , vaginal ring , preservative , abstinence . Pregnancy lactation period Participation drug study within 60 day baseline visit . Use CoQ10 within 60 day baseline visit Use antioxidant ( e.g . vitamin E , C ) within 60 day baseline visit Use drug modify mitochondrial activity within 60 day baseline visit Use statins within 60 day baseline visit ( inhibit endogenous CoQ10 production ) Use drug interfere catecholamine metabolism ( e.g . reserpine , amphetamine , monaomine oxidaseA inhibitor , methylphenidate , cinnarizine ) within 30 day baseline visit . Use Levodopa within 30 day baseline visit ( CoQ10 may change metabolism ) . An unstable dosage CNSactive drug ( e.g . anxiolytic , hypnotic , tranquillizer , antidepressant ) within 30 day baseline visit throughout study . An unstable dosage antiparkinsonian drug within 30 day baseline visit throughout study .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>Progressive Supranuclear Palsy</keyword>
	<keyword>Coenzyme Q10</keyword>
</DOC>